Abstract des Autors

Traditional steroid profiling parameters have been shown to be limited in their ability to detect the administration of transdermal testosterone gels and creams. Axiron is a recent transdermal pharmaceutical testosterone preparation for the treatment Of testosterone deficiency in men. This case study looks at the steroid profiling and GC/C/IRMS results for a multiple dose administration of Axiron (60 mg per day) to a single volunteer over a four-day period. In this case study, the steroid profiling results were reviewed using the ABP steroid passport. This led to all samples from the 3rd day of administration onwards being identified for further investigation by GC/C/IRMS. The analysis of these samples by GC/C/IRMS would have resulted in an AAF according to positivity criteria v. from the now effective WADA technical document for GC/C/IRMS.